Cytosystems Invited to MEDICA Trade Fair

Cytosystems has been invited to attend the MEDICA trade fair brokerage and pitching events in Dusseldorf 13th-16th November through their involvement in the EU Horizon 2020 scheme. The €3.2million grant which was awarded in 2015 has allowed the company to continue in their development of bladder cancer diagnostics and look towards a full clinical trial of their first product BladderLight™.

To coincide with their attendance at the trade fair, a new brochure presented by Cytosystems describes, for the first time, their technology solution for bladder cancer stratification through their product BladderLight™. BladderLight™, an integrated and automated digital pathology solution for the diagnosis and monitoring of bladder cancer, marks a step-change in non-invasive bladder cancer diagnostics.

Comprising of three component technologies, BladderLight™ provides superior accuracy by optimising each step in the diagnostic workflow, mitigating the current limitations of urine cytology and biomarker analysis.

The brochure highlights Cytosystems’ technology for cell analysis and outlines the benefits of adopting BladderLight™. It is to be introduced into the public domain during the MEDICA trade fair in Dusseldorf. Please contact This email address is being protected from spambots. You need JavaScript enabled to view it. if you would like a copy.

MCM biomarker shows over 90% sensitivity for detection of bladder cancer; poster presentation at AUA'17, Boston

Mr. Kasra Saeb-Parsy BSc, MB BS, AFHEA, FRCSEd (Urol), Consultant urologist, Cambridge University Hospitals NHS Foundation Trust presented results of a 275-patient multi-centred UK clinical trial at this year’s AUA’17 in Boston. These revolutionary results, together with additional supporting data are now available to be viewed [HERE]

The study shows the MCM assay achieves a sensitivity of 95.8% and specificity of 91.7% in the gross hematuria clinic and 92.3%/80.3% in the surveillance clinic. These results highlight Cytosystems’ ground-braking technological developments and is catapulting clinical validation of the company’s new improved user friendly test.


Clinical trial results for MCM cytology based assay to be presented at AUA’17, Boston May 12


The ground breaking results of a 275-patient multi-centered UK clinical trial will be presented at this year’s AUA conference, in Boston by Mr. Kasra Saeb-Parsy BSc, MB BS, AFHEA, FRCSEd (Urol), Consultant urologist, Cambridge University Hospitals NHS Foundation Trust 

Mr. Saeb-Parsy, one of the PI’s in the study, will be explaining how the MCM assay can achieve a sensitivity of 95.8% and specificity of 91.7% in the gross hematuria clinic and 92.3%/80.3% in the surveillance clinic.  MCM is a Minichromosome Maintenance Protein involved with the regulation of cell replication.  Healthy cells found in urine do not express MCM, whereas cells expressing MCM are indicative of cancerous cells.  Recent developments which further improve the clinical utility, accuracy, and health economic aspects of the assay will be discussed.

The presentation concludes that MCM2 detection has the potential to be the basis for a reliable non-invasive test, for diagnosis of primary and recurrent urinary carcinoma, and may be used to stratify cases where there is no likelihood of disease i.e. zero false negatives, thus avoiding invasive intervention and resulting in quantifiable health economic benefits.


Poster details:

MP15-20: MCM-2 cell based assay is a sensitive and specific test for risk stratification of bladder cancer patients.

Friday, May 12  1:00 PM - 3:00 PM


Location: BCEC: Room 252

Boost for bladder cancer detection

A pioneering new method for the accurate diagnosis of bladder cancer is one step closer thanks to a £½ million funding boost.

The funding from the UK’s innovation agency, Innovate UK, will allow experts at the University of St Andrews to develop technology alongside Aberdeen-based diagnostic specialists Cytosystems.

Read the full article here

Cytosystems Secures Innovate Grant of £500,000

Aberdeen, 19 July 2016

Cytosystems, a clinical stage diagnostic company, developing new diagnostics for bladder and prostate cancer, and the University of St Andrews have been awarded a grant of £500,000, through the UK’s innovation agency, Innovate UK.

The Award will see Cytosystems and the University of St Andrews develop an automated system for the analysis of cells isolated from urine and which have been attached to a microscope slide.  Experts in medical software development, cytopathology and urology will work together to develop software, which automatically analyses the cells, resulting in an extremely accurate test for the presence of bladder cancer. Alongside this, the team will work to create an intuitive software interface for a fully automated workflow from initial analysis to the end result.

This project will add to the current range of technologies developed by Cytosystems for the detection of bladder cancer. All of Cytosystems diagnostic technology is designed to meet a significant clinical need for a non-invasive in-vitro test for bladder cancer.

Cytosystems has developed a novel technology for urine cytology called BladderLight™. BladderLight™ is a novel stratification and risk management tool that enables a diagnosis with improved accuracy compared to current clinical practice. Furthermore, BladderLight™ is a cheaper and non-invasive alternative to the traditional method of cystoscopy; which is also both uncomfortable and has associated morbidities. This technology, when combined with their novel cell collection and processing device allows physicians to test a patients’ urine for the presence of cancer cells.

Not only will BladderLightTM aid the initial diagnosis of bladder cancer, the test will also relieve some of the burden of the management of bladder cancer post-treatment. Bladder cancer patients, due to the high recurrence of the disease, need frequent cystoscopy surveillance post treatment – up to four times per year in the first two years, then reducing to biannually, and annually after five years, which puts a considerable strain on hospital resource.

Alongside the development of the cell processing instrument and the automated analysis, the grant will also be used to secure regulatory approval in Europe and the US.

Dr Nigel McLean, Director of Product Management from Cytosystems, added: “This grant will significantly help in the development of our test for bladder cancer by reducing any further burden on already busy pathologists.  By working with the clinical and technology experts in University of St Andrews we can enhance the end-user experience and improve the scalability and adoption of the assay within the busy pathology environment.  BladderLightTM will be of great benefit to the patient and healthcare organizations. .”

Dr Peter Caie from the University of St Andrews, stated: “The cutting-edge image analysis technology involved in the BladderLightTM automated system captures complex measurements of each individual cell’s shape and size in the patient sample. It furthermore combines these single-cell resolution measurements with each cell’s protein biomarker expression thereby resulting in an extremely accurate assessment of the presence or absence of cancer cells within the urine sample.”


For further information, please contact:

Tony Stephenson
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

Cytosystems is a clinical stage diagnostic development company, currently focussed on the development of technology for the diagnosis and management of urological cancers such as bladder and prostate cancer.  The company has developed a novel technology for urine cytology called BladderLight™, that enables a diagnosis with very high accuracy, that is non-invasive thus more acceptable to patients than the current invasive procedure. Cytosystems was established in 2006, and has been developing new diagnostic technologies that not only improve diagnosis and management of bladder cancer, but are also more acceptable to patients, by being less intrusive.

Innovate UK is the UK’s innovation agency. We are business focused and drive disruptive innovation right across the UK economy, funding and connecting pioneering businesses so they can create the products, processes and industries of the future. It is our mission to boost productivity, increase exports and help the UK economy grow head and shoulders above other nations. For further information and to stay updated on our latest news visit, follow us on Twitter at @innovateuk or subscribe to our YouTube channel at



Page 1 of 2